trending Market Intelligence /marketintelligence/en/news-insights/trending/1oetpq6sjnng8rwr9sdllg2 content esgSubNav
In This List

Coherus' petitions to invalidate patent covering Amgen drug rejected

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Coherus' petitions to invalidate patent covering Amgen drug rejected

Coherus Biosciences Inc. said its petitions to invalidate Amgen Inc.'s patents covering etanercept were rejected by the U.S. Patent Trial and Appeal Board.

Etanercept is the main component of Amgen's rheumatoid arthritis drug Enbrel.

The Redwood City, Calif.-based biotechnology company was seeking to invalidate the patents in the interest of its biosimilar, CHS-0214.

The patents flagged for inter partes review cover a method for making etanercept and also the protein itself.

Amgen's patent for the medicine does not expire until 2029.